JPRN-jRCT2080221931未知2 期
Phase 2 Study of Ipilimumab Plus Dacarbazine in Japanese Patients With Previously Untreated Unresectable or Metastatic Melanoma
Bristol-Myers K.K.0 个研究点目标入组 26 人开始时间: 2012年10月1日最近更新:
适应症
试验速览
- 阶段
- 2 期
- 发起方
- 入组人数
- 26
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 20age old 至 ot applicable（—）
- 性别
- All
入选标准
- •Histologic diagnosis of malignant melanoma
- •-Previously untreated Stage III with N3 (unresectable) or Stage IV melanoma
- •-Life expectancy of at least 16 weeks in this study
- •-Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
排除标准
- •-Evidence of brain metastases on brain imaging
- •-Primary ocular or mucosal melanoma
- •-History of or current active autoimmune disease
研究者
相似试验
已完成
2 期
Phase 2 Study of Ipilimumab Plus Dacarbazine in Japanese Patients With Advanced MelanomaMelanomaNCT01681212Bristol-Myers Squibb21
进行中（未招募）
不适用
A Phase II Study of the Combination of Ipilimumab and Fotemustine in Patients with Unresectable Locally Advanced or Metastatic Malignant Melanoma - NIBIT-M1EUCTR2010-019356-50-ITIBIT (NETWORK ITALIANO PER LA BIO-IMMUNOTERAPIA DEI TUMORI)
招募中
2 期
OGIK2004(NIke Study)JPRN-jRCTs071210019Okamoto Isamu30
进行中（未招募）
1 期
Study of Nivolumab plus Ipilimumab, Ipilimumab or Cabazitaxel in Men with Metastatic Castration-Resistant Prostate CancerEUCTR2016-001928-54-DKBristol-Myers Squibb International Corporation489
进行中（未招募）
1 期
Study of Nivolumab plus Ipilimumab, Ipilimumab or Cabazitaxel in Men with Metastatic Castration-Resistant Prostate CancerMetastatic Castration-Resistant Prostate CancerMedDRA version: 21.1Level: PTClassification code: 10036909Term: Prostate cancer metastatic Class: 100000004864MedDRA version: 21.1Level: LLTClassification code: 10076506Term: Castration-resistant prostate cancer Class: 10029104CTIS2022-502909-15-00477